Artropatías inflamatorias y artritis inducidas por microcristales

Morillon MB, Norup A, Singh JA, Dalbeth N, Taylor WJ, Kennedy MA, et al. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set. Semin Arthritis Rheum. 2023; 60: 152191-152191. DOI:10.1016/j.semarthrit.2023.152191.

Abhishek A, Tedeschi SKK, Pascart T, Latourte A, Dalbeth N, Neogi T, et al. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis Rheumatol. 2023. DOI:10.1002/art.42619.

Abhishek A, Tedeschi SK, Pascart T, Latourte A, Dalbeth N, Neogi T, et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Ann Rheum Dis. 2023. DOI:10.1136/ard-2023-224575.

Schlesinger N, Perez Ruiz F, Liote F. Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol. 2023; 19(10): 640-649. DOI:10.1038/s41584-023-01006-3.

Silva Diaz M, Blanco FJ, Vila VQ, Seoane Mato D, Perez Ruiz F, Juan Mas A, et al. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables. Rheumatol Int. 2022; 42(6): 1085-1096. DOI:10.1007/s00296-021-05038-4.

Perez Ruiz F, Perez Herrero N, Gantes Pedraza MA. Gout. What's up doc?. Med Clin. 2022; 158(12): 615-621. DOI:10.1016/j.medcli.2022.01.002.

Uhlig T, Karoliussen LF, Sexton J, Kvien TK, Haavardsholm EA, Perez Ruiz F, et al. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. Arthritis Res Ther. 2022; 24(1). DOI:10.1186/s13075-022-02772-3.

Sumpter NA, Takei R, Cadzow M, Topless RKG, Phipps Green AJ, Murphy R, et al. Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout. Arthritis Rheumatol. 2023. DOI:10.1002/art.42393.

Uhlig T, Karoliussen LF, Sexton J, Kvien TK, Haavardsholm EA, Perez Ruiz F, et al. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study. Clin Rheumatol. 2022; 41(12): 3817-3823. DOI:10.1007/s10067-022-06416-4.

Uhlig T, Karoliussen L, Sexton J, Kvien TK, Haavardsholm EA, Perez Ruiz F, et al. FLUCTUATIONS IN SERUM URATE ARE RELATED TO GOUT FLARES IN THE NOR-GOUT STUDY. Ann Rheum Dis. 2022; 81: 384-385. DOI:10.1136/annrheumdis-2022-eular.1135.

Verdu RC, Pego Reigosa JM, Seoane Mato D, Valle MM, Sanchez DP, Martinez MJM et al. Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply. Rheumatology (Oxford). 2021; 60(3): 120-121. DOI:10.1093/rheumatology/keaa762.

Tedeschi SK, Pascart T, Latourte A, Godsave C, Kundakci B, Naden RP et al. Identifying potential classification criteria for calcium pyrophosphate deposition disease (CPPD): Item generation and item reduction. Arthritis Care Res. 2021. DOI:10.1002/acr.24619.

Barahona Garcia E, Modesto Caballero MC, Arostegui Lavilla J. Transient migratory osteoporosis. Med Clin. 2021; 158(3): 147-147. DOI:10.1016/j.medcli.2021.04.016.

Quilis N, Sivera F, Seoane Mato D, Perez Ruiz F, Sanchez Piedra C, Diaz Gonzalez F et al. Prevalence of gout in the adult general population in Spain: estimating the proportion of undiagnosed cases. Joint Bone Spine. 2021; 89(1): 105257-105257. DOI:10.1016/j.jbspin.2021.105257.

Castillo Vilella M, Gimenez N, Tandaipan JL, Quintana S, Modesto C. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach. Pediatr Rheumatol. 2021; 19(1). DOI:10.1186/s12969-021-00607-0.

Blanco FJ, Silva Diaz M, Quevedo Vila V, Seoane Mato D, Perez Ruiz F, Juan Mas A et al. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study. Reumatol Clin (Engl Ed). 2021; 17(8): 461-470. DOI:10.1016/j.reumae.2020.01.005.

Barahona Garcia E, Modesto Caballero MC, Arostegui Lavilla J. Intravenous iron treatment-induced hypophosphatemia. Med Clin. 2021. DOI:10.1016/j.medcli.2021.06.023.

Takei R, Cadzow M, Markie D, Bixley M, Phipps Green A, Major TJ et al. Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. J Hum Genet. 2021; 66(2): 161-169. DOI:10.1038/s10038-020-0821-z.

Takei R, Cadzow M, Markie D, Bixley M, Phipps Green A, Major TJ et al. Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects (vol 81, pg 251, 2020). J Hum Genet. 2021; 66(2): 225-225. DOI:10.1038/s10038-020-00833-6.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020; 79(1): 31-38. DOI:10.1136/annrheumdis-2019-215315.

Zaidi F, Narang RK, Phipps Green A, Gamble GG, Tausche AK, A, et al. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. Rheumatology (Oxford). 2020; 59(9): 2544-2549. DOI:10.1093/rheumatology/kez685.

Cortés Verdú R, Pego Reigosa JM, Seoane Mato D, Morcillo Valle M, Palma Sánchez D, Moreno Martínez MJ, et al. Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?. Rheumatology (Oxford). 2020. DOI:10.1093/rheumatology/kez668.

Blanco FJ, Silva Diaz M, Quevedo Vila V, Seoane Mato D, Perez Ruiz F, Juan Mas A, et al. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study. Reumatol Clin. 2020; 17(8): 461-470. DOI:10.1016/j.reuma.2020.01.008.

Taylor W, Dalbeth N, Singh JA, Rahn EJ, Mudano AS, Chen Y, et al. Flare rate thresholds for patient assessment of gout disease activity states. J Rheumatol. 2020; 48(2): 293-298. DOI:10.3899/jrheum.191242.

De Meulemeester M, Mateus E, Wieberneit Tolman H, Betteridge N, Ireland L, Petersen G, et al. Understanding the patient voice in gout: a quantitative study conducted in Europe. BJGP Open. 2020; 4(1). DOI:10.3399/bjgpopen20X101003.

Pijoán Moratalla C, Blanco Caceres BA, Bachiller Corral J. Distal intersection syndrome: An unusual cause of forearm pain. Reumatol Clin. 2020; 16(2 Pt 1): 128-129. DOI:10.1016/j.reuma.2018.02.001.

Jagpal A, Rahn EJ, Mudano AS, Dalbeth N, Taylor W, Saag KG, et al. Which factors predict discordance between a patient and physician on a gout flare?. Rheumatology (Oxford). 2020; 60(2): 773-779. DOI:10.1093/rheumatology/keaa413.

Quilis N, Vela P, Blanco Caceres BA, Diaz Torne C, Calvo Aranda E, Sivera F, et al. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. Ann Rheum Dis. 2020; 81(7). DOI:10.1136/annrheumdis-2020-218226.

Garcia P, Fernandez MG, Rivas MN, Duruelo J, Garmendia E, Lavilla JA, et al. THE IMPORTANCE OF THERAPEUTIC COMPLIANCE: ADHERENCE TO METHOTREXATE AND ITS ROLE IN IMMUNOGENICITY. Ann Rheum Dis. 2020; 79: 1464-1464. DOI:10.1136/annrheumdis-2020-eular.4803.

Browne LD, Jaouimaa F, Walsh C, Perez Ruiz F, Richette P, Burke K, et al. Serum uric acid and mortality thresholds among men and women in the Irish health system: A cohort study. Eur J Intern Med. 2020; 84: 46-55. DOI:10.1016/j.ejim.2020.10.001.

Perez Ruiz F, Perez Herrero N, Richette P, Stack AG. High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who's to Blame?. Rheumatol Ther. 2020; 7(4): 1011-1019. DOI:10.1007/s40744-020-00249-w.

Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264): 1745-1757. DOI:10.1016/S0140-6736(20)32234-0.

Lopez Gutierrez F, Garcia Fernandez A, Loarce Martos J, Calvo Sanz L, Del Bosque Granero I, Garcia V, et al. Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?. Arthritis Rheumatol. 2020; 72

Loarce Martos J, Garcia Fernandez A, Lopez Gutierrez F, Garcia V, Calvo Sanz L, Del Bosque Granero I, et al. COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study. Arthritis Rheumatol. 2020; 72

Garcia Fernandez A, Lopez Gutierrez F, Loarce Martos J, Del Bosque Granero I, Calvo Sanz L, Blanco Caceres B, et al. Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?. Arthritis Rheumatol. 2020; 72

Gaztambide S, Ramirez J, Gomez M, Montalban C, Ruiz R, Socias C, et al. Novel mutations associated with inherited human calcium-sensing receptor disorders: A clinical genetic study. Eur J Endocrinol. 2019; 180(1): 59-70. DOI:10.1530/EJE-18-0129.

Perez Ruiz F, Richette P, Stack A, Karra R, Garcia de Yebenes MJ, Carmona L. FAILURE TO REACH SERUM URATE TARGET IS ASSOCIATED WITH ELEVATED MORTALITY IN GOUT. Ann Rheum Dis. 2019; 78(2): 97-97. DOI:10.1136/annrheumdis-2019-eular.5905.

Liote F, Karra R, Kandaswamy P, Abhishek A, Scire CA, Perez Ruiz F. AN ANALYSIS OF PRESCRIPTION RECORDS OF GOUT PATIENTS IN EUROPE: EVIDENCE OF SUBOPTIMAL MANAGEMENT AND CLINICAL INERTIA. Ann Rheum Dis. 2019; 78(2): 1305-1306. DOI:10.1136/annrheumdis-2019-eular.2868.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, et al. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care Res. 2019; 71(3): 427-434. DOI:10.1002/acr.23607.

Perez Ruiz F, Jansen TL, Tausche A, Richette P, Liote F, AK, et al. Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy. Rheumatol Ther. 2019; 6(1): 101-108. DOI:10.1007/s40744-019-0143-9.

Irati U, Chinchilla Gallo PS, Hernandez Gomez S, Garcia Llorente JF, Aizpurua Manso I, Vegas Revenga N. DENSITOMETRY VALUES CHANGE WHEN STOPPING DENOSUMAB. Ann Rheum Dis. 2019; 78(2): 1896-1896. DOI:10.1136/annrheumdis-2019-eular.4338.

Presa M, Perez Ruiz F, Oyaguez I. 2ND LINE TREATMENT WITH LESINURAD AND ALLOPURINOL VERSUS FEBUXOSTAT FOR MANAGEMENT OF HYPERURICEMIA: A COST-EFFECTIVENESS ANALYSIS FOR SPANISH PATIENTS. Ann Rheum Dis. 2019; 78(2): 291-291. DOI:10.1136/annrheumdis-2019-eular.3231.

De Meulemeester M, Jansen T, Petersen G, Perez Ruiz F. EUROPEAN PATIENT VOICE IN GOUT SURVEY - SUBJECTIVE SATISFACTION IN GOUT PATIENTS VERSUS OBJECTIVE SUBOPTIMAL GOUT CARE. Ann Rheum Dis. 2019; 78(2): 153-154. DOI:10.1136/annrheumdis-2019-eular.4873.

Richette P, Perez Ruiz F, Karra R, Latourte A, Wild I, Kandaswamy P, et al. FACTORS ASSOCIATED WITH EARLY FLARES WHEN INITIATING URATE LOWERING THERAPIES. POST HOC ANALYSIS OF CLEAR 1,2 AND CRYSTAL TRIALS. Ann Rheum Dis. 2019; 78(2): 96-96. DOI:10.1136/annrheumdis-2019-eular.4679.

Blanco Caceres BA, Perez Ruiz F, Garcia Escudero P, Gonzalez Fernandez M. HOSPITAL ADMISSIONS IN PATIENTS WITH CHRONIC RHEUMATIC DISEASESRECEIVING ADALIMUMAB. DESCRIPTIVE STUDY OF A COHORT. Ann Rheum Dis. 2019; 78(2): 2085-2086. DOI:10.1136/annrheumdis-2019-eular.6405.

Garcia P, Blanco Caceres BA, Perez Ruiz F. IS THERE LIFE TO GOUT TREATMENT AFTER RHEUMATOLOGY IS OUT OF THE EQUATION?. Ann Rheum Dis. 2019; 78(2): 1299-1299. DOI:10.1136/annrheumdis-2019-eular.7091.

Garcia P, Blanco Caceres BA, Perez Ruiz F. LONG-TERM URATE-LOWERING THERAPY: IS IT `ALL LIFELONG' NECESSARY?. Ann Rheum Dis. 2019; 78(2): 1299-1300. DOI:10.1136/annrheumdis-2019-eular.7618.

Quilis Marti N, Vela Casasempere P, Blanco Caceres BA, Diaz Torne C, Calvo Aranda E, Sivera F, et al. SKIN ADVERSE EVENTS WITH FEBUXOSTAT IN GOUT PATIENTSWITH PREVIOUS SKIN REACTIONS TO ALLOPURINOL. A MULTICENTRE DESCRIPTIVE STUDY. Ann Rheum Dis. 2019; 78(2): 1309-1310. DOI:10.1136/annrheumdis-2019-eular.4394.

Perez Ruiz F. URICOSURIC DRUGS: OLD AND NEW. Rheumatology (Oxford). 2019; 58(3)

Dalbeth N, Choi HK, Joosten LB, Khanna PP, Matsuo H, Perez Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019; 5(1): 69-69. DOI:10.1038/s41572-019-0115-y.

Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, AK, Vargas Santos AB, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019; 78(11): 1592-1600. DOI:10.1136/annrheumdis-2019-215933.

Perez Ruiz F, Dalbeth N. Combination urate-lowering therapy in the treatment of gout: What is the evidence?. Semin Arthritis Rheum. 2019; 48(4): 658-668. DOI:10.1016/j.semarthrit.2018.06.004.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Res Ther. 2019; 21(1): 8-8. DOI:10.1186/s13075-018-1788-4.

Pablos JL, Navarro F, Blanco FJ, Roman Ivorra JA, Alonso A, Martin Mola E, et al. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study. Clin Exp Rheumatol. 2019; 37(3): 437-444

Seoane Mato D, Sanchez Piedra C, Silva Fernandez L, Sivera F, Blanco FJ, Perez Ruiz F, et al. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology. Reumatol Clin. 2019; 15(2): 90-96. DOI:10.1016/j.reuma.2017.06.009.

Perez Ruiz F, Dalbeth N. Gout. Rheum Dis Clin North Am. 2019; 45(4): 583-583. DOI:10.1016/j.rdc.2019.08.001.

Blanco Caceres BA, Garcia Escudero P, Gonzalez Fernandez M. VITAMIN D (25OHD) IN PATIENTS WITH CHRONIC RHEUMATIC DISEASES RECEIVING TREATMENT WITH ADALIMUMAB: DESCRIPTIVE STUDY OF A COHORT. Osteoporosis Int. 2019; 30(2): 755-756

Blanco Caceres BA, Garcia Escudero P, Arostegui Lavilla J, Rivas Zavaleta MN, Gonzalez Fernandez M. VITAMIN D (25OHD) IN PATIENTS WITH CHRONIC RHEUMATIC DISEASESRECEIVING TREATMENT WITH ADALIMUMAB. DESCRIPTIVE STUDY OF A COHORT. Ann Rheum Dis. 2019; 78(2): 1882-1882. DOI:10.1136/annrheumdis-2019-eular.7012.

Presa M, Perez Ruiz F, Oyaguez I. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients. Clin Rheumatol. 2019; 38(12): 3521-3528. DOI:10.1007/s10067-019-04739-3.

Perez Ruiz F, Richette P, Stack AG, Gurunath RK, Garcia de Yebenes MJ, Carmona L. Failure to reach uric acid target of < 0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019; 5(2). DOI:10.1136/rmdopen-2019-001015.

Pérez Ruiz F, Jansen T, Tausche AK, Juárez Campo M, Gurunath RK, Richette P. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019; 8: 212581-212581. DOI:10.7573/dic.212581.

Sumpter N, Merriman T, Reynolds R, Abhishek A, Andres M, Dalbeth N, et al. Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts. Arthritis Rheumatol. 2019; 71(10)

Perez Ruiz F, Sanchez Piedra CA, Sanchez Costa JT, Andrés M, Diaz Torne C, Jimenez Palop M, et al. Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. Rheumatol Ther. 2018; 5(1): 243-253. DOI:10.1007/s40744-017-0091-1.

Perez Ruiz F, Moreno Lledo A, Urionaguena I, Dickson AJ. Treat to target in gout. Rheumatology (Oxford). 2018; 57(1): 20-26. DOI:10.1093/rheumatology/kex442.

Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Validation of a Definition of Flare in Patients With Established Gout. Arthritis Rheumatol. 2018; 70(3): 462-467. DOI:10.1002/art.40381.

Kiltz U, Perez Ruiz F, Uhlig T, Jansen TL, Gurunath RK, Schmedt N, et al. The Prevalence and Incidence of Gout, Its Associated Comorbidities and Treatment Pattern: An Epidemiological Study from Germany. Arthritis Rheumatol. 2018; 70(9)

Perez Ruiz F, Atxotegi J. Association of HFE Genotypes with Clinical Severity in Patients with Definite Calcium Pyrophosphate Arthritis. Arthritis Rheumatol. 2018; 70(9)

Perez Ruiz F, Richette P, Stack A, Gurunath RK, Yprous MJGD, Carmona L. Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout. Arthritis Rheumatol. 2018; 70(9)

Chinchilla SP, Atxotegi J, Onaindia IU, Perez Ruiz F. RHEUMATOLOGY TALKS TO THE COMMUNITY: RESULTS OF AN EDUCATIONAL INTERVENTION. Ann Rheum Dis. 2018; 77(2): 868-868. DOI:10.1136/annrheumdis-2018-eular.5277.

Perez Ruiz I, Martinez G, Hernandez ML, Navarro R, Ferrando M, Larreategui Z, et al. Human granulosa cells express proteins of the paraoxonase family. Free Radic Biol Med. 2018; 120(1): 138-138. DOI:10.1016/j.freeradbiomed.2018.04.455.

Perez Ruiz I, Meijide S, Hernandez ML, Navarro R, Ferrando M, Larreategui Z, et al. Antioxidant status of human follicular fluid: natural versus controlled ovarian hyper-stimulated cycles. Free Radic Biol Med. 2018; 120(1): 62-62. DOI:10.1016/j.freeradbiomed.2018.04.206.

Latourte A, Soumare A, Bardin T, Perez Ruiz F, Debette S, Richette P. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis. 2018; 77(3): 328-335. DOI:10.1136/annrheumdis-2016-210767.

Shaukat A, Gosling A, Bixley M, Phipps Green A, Major TJ, Cadzow M, et al. Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout. Arthritis Rheumatol. 2018; 70(9)

Zaidi F, Phipps Green A, Tausche AK, A, Riches P, Andres M, et al. Systematic Genetic Analysis of Early-Onset Gout: ABCG2 141K Is the Strongest Predictor. Arthritis Rheumatol. 2018; 70(9)

Sanmarti R, Molina JT, Narvaez FJ, Munoz A, Garmendia E, Garcia A, et al. Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations. Arthritis Rheumatol. 2018; 70(9)

Perez Ruiz F, Desideri G. Improving adherence to gout therapy: an expert review. Therap Clin Risk Manag. 2018; 14: 793-802. DOI:10.2147/TCRM.S162956.

Cohen SB, Alonso Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018; 77(6): 914-921. DOI:10.1136/annrheumdis-2017-212245.

Kumar A, Browne LD, Li X, Adeeb F, Perez Ruiz F, Fraser AD, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study. PLoS One. 2018; 13(5). DOI:10.1371/journal.pone.0198197.

Perez Ruiz F, Chinchilla SP, Atxotegi J. ASSOCIATION BETWEEN HFE GENOTYPES AND CLINICAL SEVERITY CHARACTERISTICS OF CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS. Ann Rheum Dis. 2018; 77(2): 140-141. DOI:10.1136/annrheumdis-2018-eular.4775.

Perez Ruiz F, Richette P, Karra RG, Wild I, Hagedorn H, Kandaswamy P, et al. EFFECT OF SERUM URIC ACID (SUA) ON GOUT FLARES (GF) AND TOPHI RESOLUTION IN GOUT PATIENTS. POOLED POST HOC ANALYSIS OF CLEAR 1 & CLEAR 2 TRIALS. Ann Rheum Dis. 2018; 77(2): 658-659. DOI:10.1136/annrheumdis-2018-eular.5565.

Uson J, Garmendia E, Moragues C, de Agustin JJ, Mayordomo L, de Miguel E, et al. TO WHAT EXTENT IS INTEROBSERVER RELIABILITY FOR DETECTING ULTRASOUND URATE CRYSTAL DEPOSITS DEPENDENT ON THE EXPERIENCE OF THE ULTRASONOGRAPHER?. Ann Rheum Dis. 2018; 77(2): 809-809. DOI:10.1136/annrheumdis-2018-eular.3965.

Perez Ruiz F, Kandaswamy P, Gurunath RK, Burton H, Jansen T. A SUMMARY OF CLINICAL EVIDENCE FOR COMMONLY USED URICOSURICS FOR GOUT IN EUROPE. Ann Rheum Dis. 2018; 77(2): 1045-1045. DOI:10.1136/annrheumdis-2018-eular.3026.

Kiltz U, Perez Ruiz F, Uhlig T, Jansen TL, Karra R, Schmedt N, et al. EPIDEMIOLOGY, TREATMENT, AND HEALTH RESOURCE USE OF GOUT PATIENTS IN GERMANY: RESULTS FROM ANALYSIS OF A CLAIMS DATABASE. Value Health. 2018; 21: 7-7. DOI:10.1016/j.jval.2018.09.042.

Ogdie A, Taylor WJ, Neogi T, Fransen J, Jansen TL, Schumacher HR, et al. Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis Rheumatol. 2017; 69(2): 429-438. DOI:10.1002/art.39959.

Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017; 76(4): 632-638. DOI:10.1136/annrheumdis-2016-209467.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29-42. DOI:10.1136/annrheumdis-2016-209707.

Liu S, Perez Ruiz F, Miner JN. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. Joint Bone Spine. 2017; 84(2): 183-188. DOI:10.1016/j.jbspin.2016.04.007.

Alvaro Gracia JM, Jover JA, Garcia Vicuna R, Carreno L, Alonso A, Marsal S, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/Ila clinical trial. Ann Rheum Dis. 2017; 76(1): 196-202. DOI:10.1136/annrheumdis-2015-208918.

Chinchilla S, Urionaguena I, Perez Ruiz F. Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years. Arthritis Rheumatol. 2017; 69(10)

Merriman TR, Cadzow M, Merriman ME, Phipps Green A, Topless R, Abhishek A, et al. A Genome-Wide Association Study of Gout in People of European Ancestry. Arthritis Rheumatol. 2017; 69(10)

Perez Ruiz F, Chinchilla S. Previous Prescription of Allopurinol Reduces the Risk of Nsaids-Related Acute Kidney Injury in Patients with Gout. Arthritis Rheumatol. 2017; 69(10)

Perez Ruiz F, Chinchilla S. Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients. Arthritis Rheumatol. 2017; 69(10)

Sellas i Fernandez A, Juanola Roura X, Alonso Ruiz A, Rosas J, Medina Luezas J, Collantes Estevez E, et al. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). Rheumatol Int. 2017; 37(11): 1817-1823. DOI:10.1007/s00296-017-3814-2.

Nielsen SM, Bartels EM, Henriksen M, Waehrens EE, Gudbergsen H, Bliddal H, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017; 76(11): 1870-1882. DOI:10.1136/annrheumdis-2017-211472.

Cohen SB, Alonso Ruiz A, Klimiuk PA, Lee E, Peter N, Czeloth N, et al. Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study. Arthritis Rheumatol. 2017; 69(10)

Cohen S, Genovese MC, Choy E, Perez Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017; 76(10): 1679-1687. DOI:10.1136/annrheumdis-2016-210459.

Wang HD, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd Allah F, et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1084-1150. DOI:10.1016/S0140-6736(17)31833-0.

Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd Allah F, Abera SF, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1151-1210. DOI:10.1016/S0140-6736(17)32152-9.

Cutolo M, Cimmino MA, Perez Ruiz F. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Eur Rev Med Pharmacol Sci. 2017; 21(18): 4186-4195

Barber RM, Fullman N, Sorensen RJD, Bollyky T, McKee M, Nolte E, et al. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet. 2017; 390(10091): 231-266. DOI:10.1016/S0140-6736(17)30818-8.

Perez Ruiz F, Urionagena I, Chinchilla SP. LONG-TERM ADHERENCE TO URATE-LOWERING THERAPY IN GOUT: DO NOT BLAME ON THE PATIENTS. Ann Rheum Dis. 2017; 76(2): 368-368. DOI:10.1136/annrheumdis-2017-eular.2994.

Chinchilla SP, Urionaguena I, Perez Ruiz F. READY OR NOT? CHANGES IN THE CLINICAL PROFILE OF GOUT PATIENTS OVER THE LAST 25 YEARS. Ann Rheum Dis. 2017; 76(2): 381-381. DOI:10.1136/annrheumdis-2017-eular.5459.

Urionaguena I, Chinchilla SP, Erauzkin GG, Muniz Gomez ML, Perez Ruiz F. EFFECT OF DIALYSIS AND LOW DOSE URATE-LOWERING ON SERUM URATE LEVELS IN PATIENTS WITH GOUT. Ann Rheum Dis. 2017; 76(2): 1363-1363. DOI:10.1136/annrheumdis-2017-eular.2980.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017; 69(9): 1903-1913. DOI:10.1002/art.40159.

Nielsen SM, Bartels EM, Henriksen M, Gudbergsen H, Bliddal H, Astrup A, et al. WEIGHT LOSS FOR OVERWEIGHT AND OBESE INDIVIDUALS WITH GOUT: A SYSTEMATIC REVIEW OF LONGITUDINAL OBSERVATIONAL STUDIES. Ann Rheum Dis. 2017; 76(2): 196-196. DOI:10.1136/annrheumdis-2017-eular.2651.

Merriman TR, Cadzow M, Merriman M, Phipps Green A, Topless R, Abhishek A, et al. A GENOME-WIDE ASSOCIATION STUDY OF GOUT IN PEOPLE OF EUROPEAN ANCESTRY. Ann Rheum Dis. 2017; 76(2): 383-383. DOI:10.1136/annrheumdis-2017-eular.5634.

Cohen S, Alonso Ruiz A, Klimiuk PA, Lee E, Peter N, Sonderegger I, et al. SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE (R)-RA). Ann Rheum Dis. 2017; 76(2): 553-553. DOI:10.1136/annrheumdis-2017-eular.3405.

Perez Ruiz F. Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort. Rheumatol Ther. 2017; 4(2): 419-425. DOI:10.1007/s40744-017-0082-2.

Gaffo AL, Dalbeth N, Saag K, Singh JA, Rahn EJ, Mudano AS, et al. Validation of a Definition for Flare in Patients with Established Gout. Arthritis Rheumatol. 2017; 69(10)

Taylor WJ, Dalbeth N, Saag K, Singh JA, Rahn EJ, Mudano AS, et al. Patients with Gout Consider Zero Flares over the Previous Six or Twelve Months Necessary for a Remission State. Arthritis Rheumatol. 2017; 69(10)

"

PEREZ RUIZ F. Gota: una oportunidad de intervención en salud. Rev esp econ salud. 2017

"

Taylor WJ, Fransen J, Dalbeth N, Neogi T, Schumacher HR, Brown M, et al. Performance of classification criteria for gout in early and established disease. Ann Rheum Dis. 2016; 75(1): 178-182. DOI:10.1136/annrheumdis-2014-206364.

Edwards NL, Malouf R, Perez Ruiz F, Richette P, Southam S, DiChiara M. Computational Lexical Analysis of the Language Commonly Used to Describe Gout. Arthritis Care Res. 2016; 68(6): 763-768. DOI:10.1002/acr.22746.

Pamela Chinchilla S, Urionaguena I, Perez Ruiz F. Febuxostat for the chronic management of hyperuricemia in patients with gout. Expert Rev Clin Pharmacol. 2016; 9(5): 665-673. DOI:10.1586/17512433.2016.1162094.

de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos Vargas R, Chapman P, et al. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res. 2016; 68(5): 667-672. DOI:10.1002/acr.22741.

Borghi C, Perez Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016; 20(5): 983-992

Perez Ruiz F, Urionagueena I, Carmona Ortells L. Epidemiology and health-related services. Curr Opin Rheumatol. 2016; 28(2): 104-109. DOI:10.1097/BOR.0000000000000258.

Perez Ruiz F, Diaz Torne C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. J Med Econ. 2016; 19(6): 604-610. DOI:10.3111/13696998.2016.1149482.

Perez Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, RDEA594 203 Study GRP. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016; 75(6): 1074-1080. DOI:10.1136/annrheumdis-2015-207919.

Taylor WJ, Fransen J, Dalbeth N, Neogi T, Schumacher HR, Brown M, et al. Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. J Rheumatol. 2016; 43(1): 150-153. DOI:10.3899/jrheum.150684.

Araujo EG, Manger B, Perez Ruiz F, Thiele RG. Imaging of gout: New tools and biomarkers?. Best Pract Res Clin Rheumatol. 2016; 30(4): 638-652. DOI:10.1016/j.berh.2016.10.010.

Dalbeth N, Schumacher HR, Fransen J, Neogi T, Jansen TL, Brown M, et al. Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care Res. 2016; 68(12): 1894-1898. DOI:10.1002/acr.22896.

Nolla JM, Martínez C, García Vicuña R, Seoane Mato D, Rosario Lozano MP, Alonso A, et al. Quality standards for rheumatology outpatient clinic. The EXTRELLA project. Reumatol Clin. 2016; 12(5): 248-255. DOI:10.1016/j.reuma.2015.11.004.

Diaz Torne C, Perez Herrero N, Perez Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015; 27(2): 164-169. DOI:10.1097/BOR.0000000000000146.

Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117-171. DOI:10.1016/S0140-6736(14)61682-2.

Perez Ruiz F, Dalbeth N, Bardin T. A Review of Uric Acid, Crystal Deposition Disease, and Gout. Adv Ther. 2015; 32(1): 31-41. DOI:10.1007/s12325-014-0175-z.

Perez Ruiz F, Punzi L. Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations. Eur Rev Med Pharmacol Sci. 2015; 19(9): 1549-1552

Castrejon I, Toledano E, Piedad Rosario M, Loza E, Perez Ruiz F, Carmona L. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int. 2015; 35(7): 1127-1137. DOI:10.1007/s00296-014-3189-6.

Castrejon I, Toledano E, Rosario MP, Loza E, Perez Ruiz F, Carmona L. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis (vol 35, pg 1127, 2015). Rheumatol Int. 2015; 35(7): 1139-1139. DOI:10.1007/s00296-015-3264-7.

Neogi T, Jansen TLTHA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74(10): 1789-1798. DOI:10.1136/annrheumdis-2015-208237.

Neogi T, Jansen TLTHA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol. 2015; 67(10): 2557-2568. DOI:10.1002/art.39254.

Vos T, Barber RM, Bell B, Bertozzi Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995): 743-800. DOI:10.1016/S0140-6736(15)60692-4.

Grainger R, Dalbeth N, Keen H, Durcan L, Edwards NL, Perez Ruiz F, et al. Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. J Rheumatol. 2015; 42(12): 2460-2464. DOI:10.3899/jrheum.141164.

Perez Ruiz F, Pamela Chinchilla S, Atxotegi J, Urionagueena I, Maria Herrero Beites A, Angeles Aniel Quiroga M. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase. Rheumatol Int. 2015; 35(11): 1857-1861. DOI:10.1007/s00296-015-3355-5.

Perez Ruiz F, Angeles Aniel Quiroga M, Maria Herrero Beites A, Pamela Chinchilla S, Garcia Erauskin G, Merriman T. Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. Rheumatol Int. 2015; 35(9): 1519-1524. DOI:10.1007/s00296-015-3242-0.

Murray CJL, Barber RM, Foreman KJ, Ozgoren AA, Abd Allah F, Abera SF, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015; 386(10009): 2145-2191. DOI:10.1016/S0140-6736(15)61340-X.

Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015; 33(9): 1729-1741. DOI:10.1097/HJH.0000000000000701.

Taylor WJ, Fransen J, Jansen TL, Dalbeth N, Schumacher HR, Brown M, et al. Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout. Arthritis Care Res. 2015; 67(9): 1304-1315. DOI:10.1002/acr.22585.

Perez Ruiz F, Becker MA. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2: 9-14. DOI:10.1185/03007995.2015.1087980.

Perez Ruiz F, Marimon E, Chinchilla SP. Hyperuricaemia with deposition: latest evidence and therapeutic approach. Ther Adv Musculoskelet Dis. 2015; 7(6): 225-233. DOI:10.1177/1759720X15599734.

Perez Ruiz F, Chinchilla Gallo SP, Urionagueena I, Garmendia E. Relationship Between Ultrasonographic Synovial Inflammation and Ultrasonographic Urate Deposition Findings in Patients with Gout. Arthritis Rheumatol. 2015; 67(10)

Perez Ruiz F, Andres M, Diaz Torne C, De Miguel E, Moragues C, Sivera F, et al. Improvement in Treat to Target Serum Urate Levels: Preliminary Results from a Comparison Between Two Audits of Management. Arthritis Rheumatol. 2015; 67(10)

Terkeltaub R, Perez Ruiz F, Kopicko J, Fung M, Adler S, Storgard C, et al. The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors. Arthritis Rheumatol. 2015; 67(10)

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Adler S, et al. Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study. Arthritis Rheumatol. 2015; 67(10)

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout. Arthritis Rheumatol. 2015; 67(10)

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Adler S, et al. Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function. Arthritis Rheumatol. 2015; 67(10)

Pablos JL, Navarro Sarabia F, Blanco FJ, Roman Ivorra JA, Alonso A, Martin Mola E, et al. Switch from Tocilizumab plus Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity. Arthritis Rheumatol. 2015; 67(10)

Calvo I, Anton J, Bustabad S, Camacho M, de Inocencio J, Luz Gamir MA, et al. Consensus of the Spanish society of pediatric rheumatology for transition management from pediatric to adult care in rheumatic patients with childhood onset. Rheumatol Int. 2015; 35(10): 1615-1624. DOI:10.1007/s00296-015-3273-6.

Perez Ruiz F, Martínez Indart L, Carmona L, Herrero Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014; 73(1): 177-182. DOI:10.1136/annrheumdis-2012-202421.

Nathali Rivas Zavaleta M, Guayambuco Romero S, Calabozo Raluy M, Pérez Ruiz F. Osteomalacia induced by adefovir in patient with hepatitis B. Reumatol Clin. 2014; 10(2): 120-121. DOI:10.1016/j.reuma.2013.01.006.

Perez Ruiz F, Maria Herrero Beites A. Environment and genetics in gout: a maze for clinicians?. Nat Rev Rheumatol. 2014; 10(1): 8-9. DOI:10.1038/nrrheum.2013.173.

Perez Ruiz F, Herrero Beites AM. Gout treatment-more tablets might be needed. Nat Rev Rheumatol. 2014; 10(3). DOI:10.1038/nrrheum.2013.173-c2.

Perez Ruiz F, Chinchilla SP, Herrero Beites AM. Canakinumab for gout: a specific, patient-profiled indication. Expert Rev Clin Immunol. 2014; 10(3): 339-347. DOI:10.1586/1744666X.2014.880653.

Perez Ruiz F, Castillo E, Chinchilla SP, Herrero Beites AM. Clinical Manifestations and Diagnosis of Gout. Rheum Dis Clin North Am. 2014; 40(2): 193-193. DOI:10.1016/j.rdc.2014.01.003.

MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. Bmj Open. 2014; 4(7). DOI:10.1136/bmjopen-2014-005354.

Maria Haro J, Tyrovolas S, Garin N, Diaz Torne C, Carmona L, Sanchez Riera L, et al. The burden of disease in Spain: results from the global burden of disease study 2010. BMC Med. 2014; 12. DOI:10.1186/s12916-014-0236-9.

Richette P, Perez Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target?. Nat Rev Rheumatol. 2014; 10(11): 654-661. DOI:10.1038/nrrheum.2014.124.

Perez Ruiz F, Herrero Beites AM, Angeles Aniel Quiroga M, Chinchilla SP. Increase in Thyroid Stimulating Hormone (TSH) Levels in Patients with Gout Treated with Inhibitors of Xanthine-Oxido-Reductase. Arthritis Rheumatol. 2014; 66(10, SI): 74-75

Rasheed H, Topless R, Day R, Kannangara D, Williams K, Bradbury L, et al. Association of the Toll-like Receptor 4 (TLR4) Gene with Gout. Arthritis Rheumatol. 2014; 66(10, SI): 1294-1295

Sellas Fernandez A, Guerra Vazquez JL, Luis Casals J, Gonzalez Fernandez C, Miguelez R, Rosas J, et al. Clinical Value of ASDAS Index in Spanish Patients with Ankylosing Spondylitis. Arthritis Rheumatol. 2014; 66(10, SI): 262-262

Perez Ruiz FP. GOUT AND CRYSTAL-INDUCED DISEASES: YEAR IN REVIEW 2013-2014. Ann Rheum Dis. 2014; 73(2): 47-48. DOI:10.1136/annrheumdis-2014-eular.6166.

Perez Ruiz F, Castillo E, Chinchilla SP, Herrero Beites AM. FACTORS ASSOCIATED TO THE DEVELOPMENT OF TOPHI IN PATIENTS WITH GOUT. Ann Rheum Dis. 2014; 73(2): 776-776. DOI:10.1136/annrheumdis-2014-eular.5335.

Perez Ruiz F, Castillo E, Chinchilla SP, Herrero Beites AM. COEXISTENCE OF GOUT AND PYROPHOSPHATE ARTHRITIS IN TWO LARGE COHORTS: HYPERURICEMIA AS A FACTOR FOR CLINICAL MISDIAGNOSIS. Ann Rheum Dis. 2014; 73(2): 776-776. DOI:10.1136/annrheumdis-2014-eular.5305.

Alvaro Gracia JM, Jover JA, Garcia Vicuna R, Carreno L, Alonso A, Marsal S, et al. THE USE OF INTRAVENOUS EXPANDED ALLOGENEIC ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN REFRACTORY RHEUMATOID ARTHRITIS PATIENTS. A PHASE IB/IIA STUDY. Ann Rheum Dis. 2014; 73(2): 504-504. DOI:10.1136/annrheumdis-2014-eular.5849.

Merriman T, Topless R, Day R, Kannangara D, Williams K, Bradbury L, et al. ASSOCIATION OF THE TOLL-LIKE RECEPTOR 4 (TLR4) GENE WITH GOUT. Ann Rheum Dis. 2014; 73(2): 354-354. DOI:10.1136/annrheumdis-2014-eular.4781.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Coyfish M, et al. UPDATED EULAR EVIDENCE-BASED RECOMMENDATIONS FOR THE MANAGEMENT OF GOUT. Ann Rheum Dis. 2014; 73(2): 783-783. DOI:10.1136/annrheumdis-2014-eular.5022.

Richette P, Pascual E, Doherty M, Barskova V, Becce F, Coyfish M, et al. UPDATED EULAR EVIDENCE-BASED RECOMMENDATIONS FOR THE DIAGNOSIS OF GOUT. Ann Rheum Dis. 2014; 73(2): 783-784. DOI:10.1136/annrheumdis-2014-eular.5546.